人参皂苷Rg3纳米晶体的制备及抗肿瘤作用

Preparation and Assessment of the Antitumor Effect of Ginsenoside Rg3 Nanocrystals

目的比较人参皂苷Rg3纳米晶体和市售剂型(参一胶囊)对人肝癌HepG2和人肺腺癌A549肿瘤细胞株的体外抗肿瘤活性。方法采用沉淀法与高压均质法联用技术制备人参皂苷Rg3纳米晶体,透射电镜对纳米晶体粒径及稳定性进行考察;噻唑蓝(MTT)法评价纳米晶体和参一胶囊对HepG2和A549肿瘤细胞的抗肿瘤作用。结果所制备的人参皂苷Rg3纳米晶体平均粒径(284±14)nm,多分散系数为0.156±0.007。纳米晶体与参一胶囊对HepG2细胞的半抑制浓度(IC50)分别为(65.59±3.62),(97.64±10.48)μg·m L^(-1);对A549细胞的IC50分别为(56.36±2.14),(83.26±7.44)μg·m L-1,均差异有统计学意义(P<0.01)。结论运用沉淀法与高压均质法联用技术制备所得的人参皂苷Rg3纳米晶体多分散系数理想且粒径较小,稳定性良好。人参皂苷Rg3纳米晶体对HepG2肝癌细胞与A549肺癌细胞的抗肿瘤活性较参一胶囊高,且在高浓度时,对HepG2肝癌细胞与A549肺癌细胞抗肿瘤活性更高。

Objective To investigate the inhibitory effects of ginsenoside Rg3 nanocrystals and Shenyi capsule against the proliferation of A549 and HepG2 cells in vitro. Methods The ginsenoside Rg3 nanocrystals were prepared by precipitation combined with high pressure homogenization technique. Particle size and polydispersity index were measured by TEM, and MIT assay was performed to evaluate the inhibitory effects of ginsenoside Rg3 nanocrystals and Shenyi capsule on A549 and HepG2 cells. Results The average particle size of ginsenoside Rg3 nanocrystals was （284± 14） nm, and the PI was 0.156±0.007.The IC50 values of nanocrystals and Shenyi capsule in HepG2 cells were （65.59±3.62） and （97.64±10.48）μg · mL-1.They were （56.36±2.14） and （83.26±7.44）μg · mL-1 in A549 cells. The differences were significant（P〈0.01）. Conclusion Ginsenoside Rg3 nanocrystals prepared by precipitation combined with high pressure homogenization technique had a small particle size, an ideal polydispersity coefficient and a better stability.In contrast to Shenyi capsule, Ginsenoside Rg3 nanocrystals showed higher anti-tumour activities in vitro.There was a significant difference between two groups at high dosages.Ginsenoside Rg3 showed a higher anti-proliferative activity in A549 than in HepG2 cells.